×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
VIR – vir biotechnology, inc. (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
VIR
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/13
08:05 am
vir
Vir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-targeted, PRO-XTEN® Dual-masked T-cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer
Low
Report
Vir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-targeted, PRO-XTEN® Dual-masked T-cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer
3/4
08:00 am
vir
Vir Biotechnology (VIR) had its price target raised by HC Wainwright from $15.00 to $20.00. They now have a "buy" rating on the stock.
Medium
Report
Vir Biotechnology (VIR) had its price target raised by HC Wainwright from $15.00 to $20.00. They now have a "buy" rating on the stock.
2/28
06:33 am
vir
Vir Biotechnology Astellas Deal Puts VIR-5500 And Valuation In Focus [Yahoo! Finance]
Low
Report
Vir Biotechnology Astellas Deal Puts VIR-5500 And Valuation In Focus [Yahoo! Finance]
2/26
04:05 pm
vir
Vir Biotechnology to Participate in Upcoming Investor Conferences
Low
Report
Vir Biotechnology to Participate in Upcoming Investor Conferences
2/26
02:11 pm
vir
Vir Biotechnology (VIR) had its "outperform" rating reaffirmed by Leerink Partners.
Low
Report
Vir Biotechnology (VIR) had its "outperform" rating reaffirmed by Leerink Partners.
2/25
10:57 pm
vir
Vir Biotechnology Announces Pricing of Public Offering of Common Stock [Yahoo! Finance]
Medium
Report
Vir Biotechnology Announces Pricing of Public Offering of Common Stock [Yahoo! Finance]
2/25
10:31 pm
vir
Vir Biotechnology Announces Pricing of Public Offering of Common Stock
Medium
Report
Vir Biotechnology Announces Pricing of Public Offering of Common Stock
2/25
12:43 am
vir
A Look At Vir Biotechnology (VIR) Valuation After Astellas Collaboration On VIR-5500 And Early Phase 1 Update [Yahoo! Finance]
Medium
Report
A Look At Vir Biotechnology (VIR) Valuation After Astellas Collaboration On VIR-5500 And Early Phase 1 Update [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/10
04:01 pm
vir
Form 8-K Vir Biotechnology, Inc. For: Apr 07
Low
Report
Form 8-K Vir Biotechnology, Inc. For: Apr 07
4/7
04:51 pm
vir
Form 4 Vir Biotechnology, Inc. For: Apr 06 Filed by: De Backer Marianne
Medium
Report
Form 4 Vir Biotechnology, Inc. For: Apr 06 Filed by: De Backer Marianne
4/6
03:24 pm
vir
Form 144 Vir Biotechnology, Inc. Filed by: De Backer Marianne
Low
Report
Form 144 Vir Biotechnology, Inc. Filed by: De Backer Marianne
4/2
10:47 am
vir
Form 4 Vir Biotechnology, Inc. For: Apr 01 Filed by: SATO VICKI L
Low
Report
Form 4 Vir Biotechnology, Inc. For: Apr 01 Filed by: SATO VICKI L
3/27
01:55 pm
vir
Form SCHEDULE 13G/A Vir Biotechnology, Inc. Filed by: VANGUARD GROUP INC
Low
Report
Form SCHEDULE 13G/A Vir Biotechnology, Inc. Filed by: VANGUARD GROUP INC
3/24
04:36 pm
vir
Form 4 Vir Biotechnology, Inc. For: Mar 23 Filed by: Sabatini Brent
Medium
Report
Form 4 Vir Biotechnology, Inc. For: Mar 23 Filed by: Sabatini Brent
3/23
03:50 pm
vir
Form 4 Vir Biotechnology, Inc. For: Mar 20 Filed by: O'Byrne Jason
Low
Report
Form 4 Vir Biotechnology, Inc. For: Mar 20 Filed by: O'Byrne Jason
3/23
09:43 am
vir
Form 144 Vir Biotechnology, Inc. Filed by: Sabatini Brent
Low
Report
Form 144 Vir Biotechnology, Inc. Filed by: Sabatini Brent
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
2/25
CDC Issues Warnings on Virus; Markets Take Hit: Virus Update [Yahoo! Finance News]
61.4%
2/27 Vir Biotechnology (NYSE: VIR) was downgraded by analysts at Robert W. Baird from a "neutral" rating to an "underperform" rating. 58.5%
3/13 Vir Biotechnology (NYSE: VIR) was downgraded by analysts at Goldman Sachs Group Inc from a "buy" rating to a "neutral" rating. 21.3%
4/6 GSK and Vir Biotechnology enter collaboration to find coronavirus solutions 21.1%
3/13 Eli Lilly CEO aims to start testing coronavirus cure 'this summer' [CNBC] 14.1%
2/25 CDC Tells Americans to Start Readying for Outbreak: Virus Update [Yahoo! Finance News] 12.9%
1/15 Vir Biotechnology (VIR) Presents At 38th Annual J.P. Morgan Healthcare Conference - Slideshow [Seeking Alpha] 12.5%
3/10 Vir Biotechnology to Present at Barclays Global Healthcare Conference 10.0%
3/26 Q4/2019 12/31/2019 EPS -0.710 ZacksConsensus -0.470 ActVsEst (0.240) - Miss 7.2%
10/18 Form 4 Vir Biotechnology, Inc. For: Oct 16 Filed by: Fullerton Management Pte Ltd 5.5%
2/27 Vir Biotechnology (NYSE: VIR) was downgraded by analysts at Robert W. Baird from a "neutral" rating to an "underperform" rating. 58.5%
3/13 Vir Biotechnology (NYSE: VIR) was downgraded by analysts at Goldman Sachs Group Inc from a "buy" rating to a "neutral" rating. 21.3%
4/6 GSK and Vir Biotechnology enter collaboration to find coronavirus solutions 21.1%
3/13 Eli Lilly CEO aims to start testing coronavirus cure 'this summer' [CNBC] 14.1%
2/25 CDC Tells Americans to Start Readying for Outbreak: Virus Update [Yahoo! Finance News] 12.9%
1/15 Vir Biotechnology (VIR) Presents At 38th Annual J.P. Morgan Healthcare Conference - Slideshow [Seeking Alpha] 12.5%
3/10 Vir Biotechnology to Present at Barclays Global Healthcare Conference 10.0%
3/26 Q4/2019 12/31/2019 EPS -0.710 ZacksConsensus -0.470 ActVsEst (0.240) - Miss 7.2%
10/18 Form 4 Vir Biotechnology, Inc. For: Oct 16 Filed by: Fullerton Management Pte Ltd 5.5%
TOP News Decliners
2/28
Trending Ticker: VIR Surges as Coronavirus fears persist [Yahoo! Finance News]
-35.9%
3/9 Form 8-K Vir Biotechnology, Inc. For: Mar 03 -22.1%
4/7 Biotechs Working Closely & Feverishly With CDC for COVID-19 Vaccine Development -14.4%
3/6 Why Was Vir Biotechnology Up 74% in February? [The Motley Fool] -14.2%
10/10 Form 3 Vir Biotechnology, Inc. For: Oct 10 Filed by: Platinum International Investment Holding RSC Ltd -13.2%
4/8 Vir Biotechnology to Host Key Opinion Leader Call and Present Update on Phase 1/2 HBV Clinical Trial with siRNA VIR-2218 -11.2%
3/19 Vir Biotechnology (NYSE: VIR) was downgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "underweight" rating. -10.8%
2/12 Form 8-K Vir Biotechnology, Inc. For: Feb 12 -10.2%
3/25 Vir Biotechnology Proceeding with Two Clinical Development Candidates for COVID-19 -8.5%
4/6 GSK to partner with Vir for potential COVID-19 treatments, invest $250 mln [Reuters] -8.2%
3/9 Form 8-K Vir Biotechnology, Inc. For: Mar 03 -22.1%
4/7 Biotechs Working Closely & Feverishly With CDC for COVID-19 Vaccine Development -14.4%
3/6 Why Was Vir Biotechnology Up 74% in February? [The Motley Fool] -14.2%
10/10 Form 3 Vir Biotechnology, Inc. For: Oct 10 Filed by: Platinum International Investment Holding RSC Ltd -13.2%
4/8 Vir Biotechnology to Host Key Opinion Leader Call and Present Update on Phase 1/2 HBV Clinical Trial with siRNA VIR-2218 -11.2%
3/19 Vir Biotechnology (NYSE: VIR) was downgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "underweight" rating. -10.8%
2/12 Form 8-K Vir Biotechnology, Inc. For: Feb 12 -10.2%
3/25 Vir Biotechnology Proceeding with Two Clinical Development Candidates for COVID-19 -8.5%
4/6 GSK to partner with Vir for potential COVID-19 treatments, invest $250 mln [Reuters] -8.2%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: